Visco Vision Inc (6782) Fair Value & Analysis
Healthcare · TW · Market cap 12.3B TWD
Fair value as of: Jul 21, 2026
From 26 valuation models · updated 20 days ago
Share price +2.9% over the past month.
A solid business, screening 45% undervalued on our models.
What matters now
- The rarer combination: high quality (74/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (232.21 TWD). The market is more pessimistic than our downside scenario.
- The model range is unusually wide (232.21 TWD to 606.07 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 100.60 TWD – 358.89 TWD · fair‑value band 232.21 TWD – 606.07 TWD · the 214.00 TWD price screens below the 309.61 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Visco Vision Inc (6782) currently trades at 214.00 TWD, while our model-based Fair Value estimate is 309.61 TWD, implying the stock looks roughly 44.7% undervalued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Visco Vision Inc generated revenue of 4.5B TWD at a net margin of 20.7%. Revenue grew 29.7% year over year. It earns a return on equity of 23.6%. The balance sheet holds a net cash position of 234M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 232.21 TWD (bear case) to 606.07 TWD (bull case); at 214.00 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 34% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 45%, 6782 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (494.19 TWD) versus Asset-Based (47.03 TWD). Highest evidence: Growth DCF (80).
Notify me when 6782 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 63
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Visco Vision Inc. manufactures and sells silicone hydrogel contact lenses in Asia, Europe, and the Americas. It offers spherical, multifocal, toric, cosmetic, and color lenses. The company also provides medical and lease management services. Visco Vision Inc. was incorporated in 1998 and is based in Taoyuan City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Visco Vision Inc reported revenue of 4.2B TWD in FY2025 versus 2.0B TWD in FY2021, a compound +21.1%/yr. Reported net income was 887M TWD in FY2025, compounding +18.9%/yr from FY2021.
Watch 6782: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Visco Vision Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Visco Vision Inc (6782) overvalued or undervalued?
What is the fair value of 6782?
What is the quality score of 6782?
What is the revenue of Visco Vision Inc (6782)?
What is the net profit margin of 6782?
Does Visco Vision Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Visco Vision Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.